This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks Insiders Love Right Now

Lexicon Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

One biotechnology and drugs stock that insiders are snapping up here is Lexicon Pharmaceuticals (LXRX - Get Report), which is focused on the discovery and development of breakthrough treatments for human disease. Insiders are buying this stock into some big strength, since shares are up over 60% so far in 2012.

Lexicon Pharmaceuticals has a market cap of $1.03 billion and an enterprise value of $821 million. This stock trades at a steep valuation, with a price-to-sales of 858.99 and a price-to-book of 4.09. Its estimated growth rate for this year is 35.3%, and for next year it's pegged at 13.6%. This is a cash-rich company, since the total cash position on its balance sheet is $231.08 million and its total debt is 24.19 million.

A director and beneficial owner just bought 3 million shares, or about $6.75 million worth of stock, at $2.25 per share.

From a technical perspective, LXRX is currently trending above its 200-day moving average and below its 50-day moving average, which is neutral trendwise. This stock has recently pulled back from $2.75 right to its 200-day at $2 a share. So far, LXRX has held above its 200-day moving average.

If you're bullish on LXRX, then I would look for long-biased trades once it manages to break out above some near-term overhead resistance levels at $2.20 to $2.37 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.1 million shares. If that breakout triggers soon, then LXRX will set up to re-test or possibly take out its next major overhead resistance levels at $2.76 to $3.28 a share.
4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ENTG $13.29 0.00%
FTI $30.49 0.00%
KMI $17.76 0.00%
LXRX $13.81 0.00%
STJ $76.20 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs